You are here
Friday, May 25, 2018
NIH summit delivers recommendations to accelerate therapy development for Alzheimer’s disease
Call for transformative research agenda, open and collaborative science, to enable precision medicine.
Experts from government, academia, industry, and non-profit organizations put forward recommendations that provide a roadmap for an integrated, multidisciplinary research agenda necessary to inform priorities for Alzheimer’s disease and related dementias. The recommendations are designed to guide continued efforts to build a collaborative, multi-stakeholder research environment capable of delivering urgently needed cures for people at all stages of the disease. The recommendations are a result of a multi-step, iterative process culminating in the Alzheimer’s Disease Research Summit 2018: Path to Treatment and Prevention, which was convened by the National Institute on Aging (NIA), part of NIH at the U.S. Department of Health and Human Services, with support from the Foundation for the NIH. A reoccurring theme from the summit and in the recommendations is a precision medicine approach to Alzheimer’s treatment and prevention—the ability to develop interventions that can address the underlying disease process as well as the disease symptoms and be tailored to a person’s unique disease risk profile.
“This is a critical time in Alzheimer's research, with new opportunities to build upon what we have learned,” said NIA Director Richard J. Hodes, M.D. “We must continue to foster creative approaches that leverage emerging scientific and technological advances, establish robust translational infrastructure for rapid and broad sharing of data and research tools, and work with funding partners and other stakeholders to cultivate and sustain an open science research ecosystem.”
The research recommendations build upon the framework established by previous summits in 2012 and 2015. They place emphasis on the approaches, tools, infrastructure and partnerships needed to understand disease heterogeneity by comprehensive study of disease risk and resilience across diverse populations; increase research rigor and reproducibility; and accelerate therapy development by integrating experimental and computational approaches and propagating open science practices.
The recommendations centered around several key topics:
- Developing a better understanding of the complex and multifactorial causes of disease
- Enabling precision medicine research needed to develop interventions that can address the underlying disease process, as well as the disease symptoms, and be tailored to a person’s unique disease risk profile for Alzheimer’s disease
- Enhancing the research infrastructure and developing translational tools to accelerate therapy development
- Supporting the development of novel therapeutics that target the many facets of Alzheimer’s disease
- Understanding the impact of the environment and its interaction with genetic and biological factors to advance effective prevention strategies for Alzheimer’s disease
- Leveraging emerging digital technologies and big data approaches to improve our ability to discover early markers of disease, better track responsiveness to treatment and provide better care
- Bringing together multiple stakeholders to build a new research ecosystem based on the principles of open science
More than 80 leading experts joined to develop the research recommendations. They were considered and adopted by the National Advisory Council on Aging at its meeting on May 22 and 23 and will be used to update and expand specific milestones for achieving the prime research goal of the National Plan to Address Alzheimer’s Disease — to treat and prevent Alzheimer’s disease and related dementias by 2025.
About the National Institute on Aging: The NIA leads the federal government effort conducting and supporting research on aging and the health and well-being of older people. The NIA is designated as the lead NIH institute for information on Alzheimer’s disease. It provides information on age-related cognitive change and neurodegenerative disease, including participation in clinical studies, specifically on its website at www.nia.nih.gov/health/alzheimers.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®